Krystal Biotech, Inc. 8-K

What Happened

• Krystal Biotech, Inc. (KRYS) filed a Form 8‑K on May 4, 2026 (Item 2.02) to announce its financial results for the quarter ended March 31, 2026. The company attached a press release as Exhibit 99.1 that contains the detailed results. The Form 8‑K was signed by Krish S. Krishnan, Chairman and Chief Executive Officer.
• The filing includes the standard disclosure that the financial-results information in the 8‑K and Exhibit 99.1 is not being “filed” for purposes of Section 18 of the Securities Exchange Act and is not incorporated by reference into future registration statements unless expressly stated.

Key Details

• Filing date: May 4, 2026.
• Quarter covered: quarter ended March 31, 2026 (Q1 2026).
• Exhibit attached: Press Release (Exhibit 99.1) with the reported results.
• Signed by: Krish S. Krishnan, Chairman and CEO.

Why It Matters

• This 8‑K notifies investors that Krystal has released its quarterly earnings/financial results; the press release (Exhibit 99.1) will contain the revenue, profit/loss, and other operating metrics investors watch.
• Retail investors should read the attached press release for the specific financial figures and any management commentary, and monitor subsequent filings (e.g., the company’s quarterly report on Form 10‑Q) for audited financial statements and additional detail.